Ongoing Clinical Trials for Epstein-Barr Virus Infection Reactivation
Currently, there is 1 ongoing clinical trial investigating new treatments for Epstein-Barr Virus infection reactivation. This trial is focused on reducing fatigue, one of the most debilitating symptoms associated with this viral infection. The study is taking place in Belgium and is evaluating two investigational medications.
Clinical trial locations
Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection
This clinical trial is investigating whether two medications, 2LEBV and 2LXFS, can effectively reduce fatigue in patients with Epstein-Barr Virus infection. The study is being conducted in Belgium and will last for six months.
Who can participate:
- Patients aged 12 years or older, both male and female
- Individuals who have experienced significant fatigue for at least one month
- Those who have at least two additional symptoms, such as fever, sore throat, muscle pain, swollen lymph nodes, headaches, nausea, sleep problems, or loss of appetite
- Patients who have positive blood test results showing antibodies to Epstein-Barr Virus, indicating current or past infection
- Those willing to undergo blood tests including serology testing and lymphocyte typing
- Participants who can understand and follow study requirements and provide informed consent (with parent or legal representative consent for minors)
Who cannot participate:
- Individuals who do not have an Epstein-Barr Virus infection
What the trial involves:
The study is designed to compare the effectiveness of 2LEBV and 2LXFS against a placebo in reducing fatigue. Participants will be randomly assigned to one of three groups: one receiving 2LEBV, one receiving 2LXFS, or one receiving a placebo. The trial is double-blind, meaning neither the participants nor the researchers will know which treatment is being given, which helps ensure unbiased results.
The treatment is taken in pill form through the mouth, where it is absorbed through the mucous membranes. Throughout the six-month study period, participants will attend regular check-ups to monitor their progress and any changes in their symptoms.
At the beginning of the study, participants will undergo comprehensive screening including blood tests to confirm eligibility. During the trial, they will complete questionnaires to evaluate their level of fatigue using a tool called the MFI-20 questionnaire, which measures physical fatigue, activity levels, motivation, and mental fatigue. Evaluations will occur at the midpoint and at the end of the treatment period, with a follow-up visit to monitor long-term effects.
Investigational drugs being tested:
The study is testing two medications: 2LEBV and 2LXFS. Both are investigational drugs being evaluated specifically for their ability to reduce fatigue in patients with Epstein-Barr Virus infection. These medications are administered orally and contain various substances involved in immune system responses, including deoxyribonucleic acid (DNA), interleukin-1, interleukin-2, and interferon alfa. These substances help the body’s immune system respond to infections.
The main goal of the study is to determine whether these treatments can effectively reduce the severity of fatigue compared to a placebo. The study will also carefully monitor the safety of the treatments by recording any side effects that participants experience.
Summary
There is currently one active clinical trial for Epstein-Barr Virus infection reactivation, focusing specifically on managing fatigue, which is one of the most challenging symptoms for patients. The trial is taking place in Belgium and represents an important step in understanding whether the investigational medications 2LEBV and 2LXFS can provide relief for patients suffering from persistent fatigue related to this viral infection.
The study uses a rigorous double-blind, placebo-controlled design to ensure reliable results. It is open to both adolescents and adults, making it accessible to a broad range of patients who meet the eligibility criteria. The six-month duration allows researchers to assess both short-term and longer-term effects of the treatments on fatigue levels and overall quality of life.
For patients experiencing prolonged fatigue and other symptoms following Epstein-Barr Virus infection, this trial offers an opportunity to access new treatment approaches while contributing to scientific understanding of how to better manage this condition.